In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
<h4>Background</h4>Matrix metalloproteinases (MMPs) released by glial cells are important mediators of neuroinflammation and neurologic damage in HIV infection. The use of antiretroviral drugs able to combat the detrimental effect of chronic inflammation and target the exaggerated MMP ac...
Guardado en:
Autores principales: | Pasqua Gramegna, Tiziana Latronico, Maria Teresa Branà, Gaetano Di Bari, Fabio Mengoni, Valeria Belvisi, Maria T Mascellino, Miriam Lichtner, Vincenzo Vullo, Claudio M Mastroianni, Grazia M Liuzzi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6deeda565a33498bb67337185076b4f1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Thore Lorenzen
Publicado: (2010) -
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model.
por: Laura Ochoa-Callejero, et al.
Publicado: (2013) -
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: María Rosa López-Huertas, et al.
Publicado: (2017) -
Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases
por: Ilaria Sauzullo, et al.
Publicado: (2018) -
Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are localized in the nucleus of retinal Müller glial cells and modulated by cytokines and oxidative stress.
por: Eun-Jin Lee, et al.
Publicado: (2021)